JP7772597B2 - 生物学的送達ビヒクルのための組成物及び方法 - Google Patents
生物学的送達ビヒクルのための組成物及び方法Info
- Publication number
- JP7772597B2 JP7772597B2 JP2021573887A JP2021573887A JP7772597B2 JP 7772597 B2 JP7772597 B2 JP 7772597B2 JP 2021573887 A JP2021573887 A JP 2021573887A JP 2021573887 A JP2021573887 A JP 2021573887A JP 7772597 B2 JP7772597 B2 JP 7772597B2
- Authority
- JP
- Japan
- Prior art keywords
- mol
- lipid
- delivery vehicle
- glycero
- dialkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
- A61K47/6909—Micelles formed by phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861852P | 2019-06-14 | 2019-06-14 | |
| US62/861,852 | 2019-06-14 | ||
| US201962948095P | 2019-12-13 | 2019-12-13 | |
| US62/948,095 | 2019-12-13 | ||
| PCT/US2020/037579 WO2020252375A1 (en) | 2019-06-14 | 2020-06-12 | Compositions and methods for biological delivery vehicles |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538797A JP2022538797A (ja) | 2022-09-06 |
| JPWO2020252375A5 JPWO2020252375A5 (https=) | 2023-07-10 |
| JP2022538797A5 JP2022538797A5 (https=) | 2023-07-10 |
| JP7772597B2 true JP7772597B2 (ja) | 2025-11-18 |
Family
ID=73781318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573887A Active JP7772597B2 (ja) | 2019-06-14 | 2020-06-12 | 生物学的送達ビヒクルのための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220296516A1 (https=) |
| EP (1) | EP3982932A4 (https=) |
| JP (1) | JP7772597B2 (https=) |
| CN (1) | CN114286671A (https=) |
| AU (1) | AU2020290516B2 (https=) |
| CA (1) | CA3142949A1 (https=) |
| IL (1) | IL288755A (https=) |
| WO (1) | WO2020252375A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| US20230023615A1 (en) * | 2019-12-13 | 2023-01-26 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| EP4259099A1 (en) * | 2020-12-14 | 2023-10-18 | Particella, Inc. | Biological delivery systems |
| WO2022260678A1 (en) * | 2021-06-11 | 2022-12-15 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| JPWO2022176953A1 (https=) * | 2021-02-17 | 2022-08-25 | ||
| WO2022211481A1 (ko) * | 2021-04-01 | 2022-10-06 | 에스엔제이 파마 인크 | 생활성물질의 경구용 나노입자 및 이의 제조방법 |
| KR102789632B1 (ko) * | 2021-04-01 | 2025-04-01 | 에스엔제이 파마 인크 | 생활성물질의 경구용 나노입자 및 이의 제조방법 |
| WO2023182812A1 (ko) * | 2022-03-22 | 2023-09-28 | 주식회사 바이오엔 | 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도 |
| CN117247359A (zh) * | 2022-06-09 | 2023-12-19 | 中国科学院广州生物医药与健康研究院 | 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用 |
| WO2024006863A1 (en) * | 2022-06-30 | 2024-01-04 | Precision NanoSystems ULC | Lipid nanoparticle formulations for vaccines |
| CN118356505A (zh) * | 2023-01-10 | 2024-07-19 | 复旦大学 | 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途 |
| AU2023457271A1 (en) * | 2023-06-28 | 2025-12-18 | Global Life Sciences Solutions Canada Ulc | Lipid nanoparticle formulations for cell therapy and related methods |
| WO2025021286A1 (en) * | 2023-07-23 | 2025-01-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | A drug delivery system for increased endosomal escape |
| WO2025036297A1 (zh) * | 2023-08-11 | 2025-02-20 | 浙江海昶生物医药技术有限公司 | 一种具有靶向性的脂质组合物及其制备方法 |
| US20250082776A1 (en) * | 2023-08-31 | 2025-03-13 | Massachusetts Institute Of Technology | Polyanion coated lipid nanoparticles and methods of use thereof |
| PL248770B1 (pl) * | 2023-11-23 | 2026-01-26 | Politechnika Wroclawska | Bilosomy o dodatnim ładunku i sposób ich wytwarzania |
| WO2025151073A1 (en) * | 2024-01-10 | 2025-07-17 | Agency For Science, Technology And Research | Composition and nanoparticle suitable for use in the delivery of a therapeutic agent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149785A1 (en) | 2009-06-26 | 2010-12-29 | Universiteit Gent | Cationic liposomes for the delivery of high molecular weight compounds |
| WO2011075656A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
| JP2014511381A (ja) | 2011-02-22 | 2014-05-15 | レオ ファーマ アクティーゼルスカブ | ケラチノサイトへの結合のための環状ペプチドおよびその結合体 |
| JP2017533280A (ja) | 2014-10-31 | 2017-11-09 | ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation | 胆汁酸粒子の組成物及び方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100817024B1 (ko) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| US11219634B2 (en) * | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| BR112019008481A2 (pt) * | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| EP3558356A2 (en) * | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| WO2019046809A1 (en) * | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
-
2020
- 2020-06-12 AU AU2020290516A patent/AU2020290516B2/en active Active
- 2020-06-12 WO PCT/US2020/037579 patent/WO2020252375A1/en not_active Ceased
- 2020-06-12 US US17/619,036 patent/US20220296516A1/en active Pending
- 2020-06-12 JP JP2021573887A patent/JP7772597B2/ja active Active
- 2020-06-12 CA CA3142949A patent/CA3142949A1/en active Pending
- 2020-06-12 EP EP20821834.7A patent/EP3982932A4/en active Pending
- 2020-06-12 CN CN202080056429.6A patent/CN114286671A/zh active Pending
-
2021
- 2021-12-07 IL IL288755A patent/IL288755A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149785A1 (en) | 2009-06-26 | 2010-12-29 | Universiteit Gent | Cationic liposomes for the delivery of high molecular weight compounds |
| WO2011075656A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
| JP2014511381A (ja) | 2011-02-22 | 2014-05-15 | レオ ファーマ アクティーゼルスカブ | ケラチノサイトへの結合のための環状ペプチドおよびその結合体 |
| JP2017533280A (ja) | 2014-10-31 | 2017-11-09 | ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation | 胆汁酸粒子の組成物及び方法 |
Non-Patent Citations (2)
| Title |
|---|
| Manish Singh et al.,Unraveling the impact of hydroxylation on interactions of bile acid cationic lipids with model membranes by in-depth calorimetry studies,Phys.Chem.Chem.Phys.,2014年,16,19266-19274,DOI: 10.1039/c4cp02283a |
| Yoshiyuki Hattori et al.,Transdermal Delivery of Small Interfering RNA with Elastic Cationic Liposomes in Mice,Journal of Pharmaceutics,2013年,Article ID:149695,1-6,DOI: 10.1155/2013/149695 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3142949A1 (en) | 2020-12-17 |
| CN114286671A (zh) | 2022-04-05 |
| JP2022538797A (ja) | 2022-09-06 |
| EP3982932A4 (en) | 2023-10-25 |
| IL288755A (en) | 2022-02-01 |
| AU2020290516A2 (en) | 2022-03-31 |
| EP3982932A1 (en) | 2022-04-20 |
| AU2020290516A1 (en) | 2022-01-20 |
| US20220296516A1 (en) | 2022-09-22 |
| WO2020252375A1 (en) | 2020-12-17 |
| AU2020290516B2 (en) | 2026-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7772597B2 (ja) | 生物学的送達ビヒクルのための組成物及び方法 | |
| US20230023615A1 (en) | Compositions and methods for biological delivery vehicles | |
| Degors et al. | Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors | |
| WO2022260678A1 (en) | Compositions and methods for biological delivery vehicles | |
| US20240058454A1 (en) | Biological delivery systems | |
| AU2012255194B2 (en) | Charge triggering of self-organized nanoparticles | |
| US20190351071A1 (en) | Structures and methods for gene therapy | |
| JPWO2008120815A1 (ja) | がん細胞および癌随伴線維芽細胞への標的化剤 | |
| US20240197636A1 (en) | Tissue-specific nucleic acid delivery by mixed cationic lipid particles | |
| US20250041325A1 (en) | Lipid-based compositions and methods thereof | |
| US20210177982A1 (en) | Mucus-penetrating peptides, delivery vehicles and methods of therapy | |
| US9976142B2 (en) | Targeting molecule and a use thereof | |
| KR20140069269A (ko) | 상보성 올리고뉴클레오티드 링커를 사용한 표적화된 나노입자들의 원격 조립 | |
| US20240269318A1 (en) | Nano-delivery systems comprising modified lipids and use thereof | |
| US20150017098A1 (en) | Carrier that targets fucosylated molecule-producing cells | |
| JP5615509B2 (ja) | フコシル化糖鎖産生細胞用物質送達担体 | |
| JP5871247B2 (ja) | フコシル化糖鎖産生細胞用物質送達担体 | |
| CN117241780A (zh) | 生物递送系统 | |
| JP5936002B2 (ja) | 組合わせ医薬製剤 | |
| Park | Enhancing Cytosolic Delivery and Gene Regulation Activity of Spherical Nucleic Acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250603 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251007 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251106 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7772597 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |